LAPINJECT VHD

Main information

  • Trade name:
  • LAPINJECT VHD
  • Pharmaceutical form:
  • Suspension for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • LAPINJECT VHD
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Rabbit haemmorhagic disease virus vaccine
  • Therapeutic area:
  • Rabbit

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0163/001
  • Authorization date:
  • 13-02-2012
  • EU code:
  • FR/V/0163/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

1/5 Dokument1

ANNEXI

SUMMARYOFPRODUCTCHARACTERISTICS

2/5 Dokument1

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Syncrostim500IUlyophilisateandsolventforsolutionforinjectionforcattleandsheep

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Lyophilisatevialscontains:

Activesubstance:

EquineserumGonadotrophin(eCG,formerlyknownasPMSG)...............500IU

Solventvialcontains:

Benzylalcohol.......................................................................................16.5mg/ml

Reconstitutedsolutionfor1doseof2mlcontains:

Activesubstances

EquineserumGonadotrophin(eCG,formerlyknownasPMSG) 500IU

Excipients

Benzylalcohol 33.0mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Lyophilisateandsolventforsolutionforinjection

Lyophilisate:freeze-driedproductintheformofpowderagglomeratedincotton-likepellets.

Solvent:clearcolourlesssolution.

Reconstitutedsolution:clearcolourlesssolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle,Sheep.

4.2 Indicationsforuse,specifyingthetargetspecies

Innoncyclingcattle(cowsandheifers)andinewesandewe-lambs:

Inductionandsynchronizationofoestrusandovulation.Tobeusedincombinationwithaprogestagen.

4.3 Contraindications

Seesection4.7.

4.4 Specialwarningsforeachtargetspecies

None.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

3/5 Dokument1

Incaseofanaphylacticshock,symptomatic treatment(e.g.adrenalineorcorticosteroids)shouldbe

administered.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Careshouldbetakenwhenhandlingtheproducttoavoidself-injection.Incaseofaccidentalself-

injection,seekmedicaladvice,andshowthepackageleaflet.

Washhandsafterhandlingtheproduct.

StudiesinlaboratoryanimalsexhibitedteratogeniceffectsaftertheadministrationofeCG.Pregnant

women,thoseintendingtobecomepregnant,orwhosepregnancystatusisunknown,shouldnotusethe

product.

Accidentalspillageontheskinshouldbewashedoffimmediatelywithsoapandwater.

4.6 Adversereactions(frequencyandseriousness)

eCGisanexogenousproteinforspeciesotherthanequine.Therefore,antigen-antibodyreactionsmay

result.Inveryrarecases,repeatedadministrationsofeCGcanprovokeanaphylacticshock(see

section4.5).

4.7 Useduringpregnancy,lactationorlay

StudiesinlaboratoryanimalshaveshownteratogeniceffectsafteradministrationofeCG.

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancyandlactation.

Donotuseduringpregnancy

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Intramuscularuse.

500IUofEquineserumgonadotrophin(eCG)peranimalinoneadministrationcorrespondingto2mlof

thereconstitutedsolution.

Dissolvethelyophilisatewith2mlofsolvent.Mixuntilcompletelydissolvedtoobtainahomogenous

solution.

Thereconstitutedsolutionshouldbeusedimmediately.

Theproductshouldbeadministeredatthetimeoftheprogestagendevicewithdrawal.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationofhigherdosesthanrecommendeddosesmayincreasetheriskoftwinsincattleand

tripletsinsheep.

4.11Withdrawalperiod(s)

Meatandoffal:zerodays

Milk:zerodays

4/5 Dokument1

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:gonadotropins

ATCvetcode:QG03GA03

5.1 Pharmacodynamicproperties

EquineSerumGonadotrophin(eCG,inthepastcalledPMSG)isalargeglycoproteinsecretedduring

pregnancyinthemareanditsstructureissimilartotheendogenousgonadotrophinhormones:FSHand

LH.

eCGexertsitseffectsonFSHandLHreceptorsoftargetcellsdistributedinthegonads:infemales,

eCGsupportstheovarianfollicularmaturationbystimulatingthegrowthanddevelopmentofantral

follicles.Inovineandinnon-cyclingbovinefemale,itsuseisrecommendedafteratreatmentforthe

synchronizationofœstruswithaprogestagen:eCGimprovesfolliclematurationandovulationrateand

allowssynchronizationofovulation.

5.2 Pharmacokineticparticulars

Inplasma,eCGdeclinesbiphasicallywithspeciesterminalhalf-livesof22-64hoursand118-220hours

asmeasuredinsheep(i.v.,i.m.)andcows(i.v.,i.m.)respectively.

eCGismainlydegradedinliverandkidneyandeliminatedintheurine.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Lyophilisate:Mannitol.

Solvent:

Benzylalcohol.

Sodiumchloride.

Waterforinjections.

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:30months

Solvent:shelf-lifeafterfirstopeningthevial:28days.

Shelflifeafterreconstitutionaccordingtodirections:useimmediately.

6.4.Specialprecautionsforstorage

Lyophilisate:protectfromlight.

Storeinarefrigerator(2

C-8

C)

5/5 Dokument1

6.5 Natureandcompositionofimmediatepackaging

Primarypackaging:

Lyophilisate:

ColourlessglassvialtypeIclosedwithachlorobutylstopperandaluminiumcapsule.

Solvent:

ColourlessglassvialtypeIIclosedwithachlorobutylstopperandaluminiumcapsule.

Packsizes:

Cardboardboxcontaining5vialsoflyophilisateandonevialof10mlsolvent

Cardboardboxcontaining10vialsoflyophilisateand2vialsof10mlsolvent

Cardboardboxcontaining25vialsoflyophilisateandonevialof50mlsolvent

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialsshouldbedisposedofinaccordancewithnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

13-12-2018

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017

Published on: Wed, 12 Dec 2018 This report of the European Food Safety Authority and the European Centre for Disease Prevention and Control presents the results of zoonoses monitoring activities carried out in 2017 in 37 European countries (28 Member States (MS) and nine non-MS). Campylobacteriosis was the commonest reported zoonosis and its EU trend for confirmed human cases increasing since 2008 stabilised during 2013–2017. The decreasing EU trend for confirmed human salmonellosis cases since 2008 end...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

19-6-2018

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Merial)

Aftovaxpur Doe (Active substance: purified, inactivated foot-and-mouth disease virus strains O1 Manisa, O1 BFS, O Taiwan 3/97, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia 1 Shamir, SAT2 Saudi Arabia) - Centralised - Renewal - Commission Decision (2018)3891 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2292/R/8

Europe -DG Health and Food Safety